Ozone therapy in chemotherapy induced neuropathy

Efficacy of ozone therapy in chemotherapy induced neuropathy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240925063161N1

Enrollment

Registered

2024-10-02

Start date

2024-10-24

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced neuropathy.

Interventions

Intervention 1: Intervention group: Patients who have been treated with a standard dose of ozone gas. Intervention 2: Control group: Patients who did not receive any intervention.

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients suffered neuropathy at least one months after starting chemotherapy Patients expected life span more than 6 months Patients without favism Patients without Hemoglobinopathies Patients without uncontrolled coagulation disorder Patients with platelet more than 40000

Exclusion criteria

Exclusion criteria: Patients don'ts enough cooperation Patients with other deadly complication due to background malignancy Patients show sensivity due to ozone therapy Patients for any reasons had neuropathy before starting chemotherapy such as (diabetes mellitus ,autoimmune diseases)

Design outcomes

Primary

Measure	Time frame
Examination score of diapason before and after intervention in two ozone therapy and control groups. Timepoint: At the beginning of the study and then every ten sessions of ozone therapy. Method of measurement: Grading based on the correct answers of patients in the standard examination of neuropathy with diapason.;Examination score with monofilaman before and after the intervention in two ozone therapy and control groups. Timepoint: At the beginning of the patient's arrival in study and then every 10 sessions until the end of the study. Method of measurement: Grading based on standard clinical examination with monofilament.;Findings of the nerve and muscle bands before and after the intervention in the two ozone therapy and control groups. Timepoint: At the beginning of patients entering the study and at the end of the ozone therapy period. Method of measurement: Performing a nerve and muscle strip test.;Quality of life questionnaire scores of patients before and after the intervention in the two ozone therapy and control groups. Timepoint: At the beginning of patients entering the study and at the end of the ozone therapy period. Method of measurement: Quality of life questionnaire score based on QLC30 and Iranian society culture.	—

Measure

Time frame

Examination score of diapason before and after intervention in two ozone therapy and control groups. Timepoint: At the beginning of the study and then every ten sessions of ozone therapy. Method of measurement: Grading based on the correct answers of patients in the standard examination of neuropathy with diapason.;Examination score with monofilaman before and after the intervention in two ozone therapy and control groups. Timepoint: At the beginning of the patient's arrival in study and then every 10 sessions until the end of the study. Method of measurement: Grading based on standard clinical examination with monofilament.;Findings of the nerve and muscle bands before and after the intervention in the two ozone therapy and control groups. Timepoint: At the beginning of patients entering the study and at the end of the ozone therapy period. Method of measurement: Performing a nerve and muscle strip test.;Quality of life questionnaire scores of patients before and after the intervention in the two ozone therapy and control groups. Timepoint: At the beginning of patients entering the study and at the end of the ozone therapy period. Method of measurement: Quality of life questionnaire score based on QLC30 and Iranian society culture.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Izadi

Bagheiat-allah University of Medical Sciences

morteza_izadi@yahoo.com+98 21 8605 1163

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026